Davila and colleagues report a Phase I trial using CD19-specific chimeric antigen receptor (CAR)-engineered T cells for autologous transplant. The 16 patients with relapsed or refractory B cell acute lymphoblastic leukaemia (B-ALL) exhibited an 88% overall complete response rate. The authors also characterized diagnostic criteria and identified an already available test for the development of severe cytokine release syndrome, which is a complication of T cell transplant that requires therapeutic intervention.
References
Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Trans. Med. 6, 224ra25 (2014)
Rights and permissions
About this article
Cite this article
Alderton, G. Promising results from autologous T cell transfer. Nat Rev Cancer 14, 215 (2014). https://doi.org/10.1038/nrc3716
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3716